Follicular lymphomaNews & Research
15 curated articles for Follicular lymphoma — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Clinical drug investigation Apr 22, 2026
Cost-Effectiveness Analysis of PI3K Inhibitors for Relapsed or Refractory Follicular Lymphoma in China: A Comparison Between Linperlisib and Duvelisib.
Linperlisib, a highly selective PI3K-δ inhibitor, was firstly approved in China in November 2022 for the treatment of patients with relapsed or refractory follicular lymphoma (r/r FL) who had received at least two prior lines of systemic therapy (3L+ FL), demonstrating compelling clinical effi...
Why it matters: Recent peer-reviewed research on Follicular lymphoma that may be relevant for patients and caregivers.
- Communications biology Apr 21, 2026
Spatial profiling uncovers multicellular dynamics in early relapse of hepatitis B virus-associated follicular lymphoma.
Hepatitis B virus (HBV) infections are associated with an increased risk of B-cell lymphomas, including follicular lymphoma (FL). Chronic HBV infection and shifts in infection status following treatment can influence lymphomagenesis and immune reprogramming, potentially affecting clinical outcomes. ...
Why it matters: Recent peer-reviewed research on Follicular lymphoma that may be relevant for patients and caregivers.
- Nature Apr 21, 2026
Cell-free chromatin state tracing reveals disease origin and therapy responses.
Cell-free DNA in blood originates from fragmented chromatin released by dying cells from both healthy and diseased tissues 1,2 . These fragments carry rich molecular modalities that can reveal pathological alterations in tissues of origin 3-10 . Here we develop cf-EpiTracing, a highly sensitive auto...
Why it matters: Recent peer-reviewed research on Follicular lymphoma that may be relevant for patients and caregivers.
- JAMA oncology Apr 16, 2026
Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.
Follicular lymphoma (FL) has historically been regarded as incurable, with patients experiencing late relapses after initial chemoimmunotherapy treatment. To provide 15-year follow-up data from the SWOG S0016 trial that evaluated the potential for long-term remission and cure following chemoimmunoth...
Why it matters: Recent peer-reviewed research on Follicular lymphoma that may be relevant for patients and caregivers.
- American journal of hematology Apr 7, 2026
Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.
Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed. We report the primary analysis of pharma...
Why it matters: Recent peer-reviewed research on Follicular lymphoma that may be relevant for patients and caregivers.
- Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc Mar 20, 2026
Biomarkers Informed by Single-Cell and Spatial Transcriptomics-Biomarkers for Grade 3 Follicular Lymphoma.
Follicular lymphoma (FL) patients have variable outcomes, underscoring the need for biomarkers for improved risk stratification. Current FL grading systems, based on subjective centroblast counts, suffer from poor reproducibility, despite evidence linking grade 3 FL to worse prognosis. We aimed to i...
Why it matters: Recent peer-reviewed research on Follicular lymphoma that may be relevant for patients and caregivers.
- Virchows Archiv : an international journal of pathology Mar 9, 2026
Ocular adnexa follicular lymphoma: clinicopathological study of 23 patients.
Follicular lymphoma (FL) spans both nodal and extranodal sites, with molecular characteristics that may vary by anatomical location. While nodal FL typically shows BCL2 rearrangement and frequent chromatin-modifying gene mutations (CREBBP, KMT2D), some extranodal FLs lack t(14;18)(q32:q21) and harbo...
Why it matters: Recent peer-reviewed research on Follicular lymphoma that may be relevant for patients and caregivers.
- Human pathology Mar 8, 2026
Three practice updates in non-Hodgkin lymphoma for 2026.
Lymphoid neoplasms present many challenges in routine surgical pathology practice, given the numerous forms of non-Hodgkin lymphoma that must be distinguished from each other through careful morphologic evaluation supplemented by an ever-growing battery of ancillary studies that may include immunohi...
Why it matters: Recent peer-reviewed research on Follicular lymphoma that may be relevant for patients and caregivers.
- European journal of haematology Mar 7, 2026
Chemotherapy-Sparing Strategies in Follicular Lymphoma: Emerging Targeted and Immune-Based Approaches.
Follicular lymphoma (FL), traditionally considered an indolent yet incurable malignancy, is experiencing a substantial evolution in its therapeutic landscape with the emergence of chemo-free treatment strategies. These novel approaches challenge conventional chemotherapy-based paradigms and offer pr...
Why it matters: Recent peer-reviewed research on Follicular lymphoma that may be relevant for patients and caregivers.
- Blood advances Mar 6, 2026
Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.
Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Although patients with FL have high response rates to therapy, most develop increasingly resistant disease. In addition, transformation into an aggressive lymphoma is associated with unfavorable outcomes. Many novel agents ar...
Why it matters: Recent peer-reviewed research on Follicular lymphoma that may be relevant for patients and caregivers.
- Blood advances Feb 26, 2026
Real-World Outcomes and Toxicities of CAR-T in Relapsed/Refractory Follicular Lymphoma: A Multicenter Cohort Study.
Chimeric antigen receptor T-cell (CAR-T) therapy revolutionized treatment of relapsed/refractory (R/R) follicular lymphoma (FL). Real-world efficacy and toxicity data are needed as clinical trial populations are often not representative. Hence, we conducted a multi-center retrospective study of pati...
Why it matters: Recent peer-reviewed research on Follicular lymphoma that may be relevant for patients and caregivers.
- Virchows Archiv : an international journal of pathology Feb 23, 2026
Unusual case of follicular lymphoma of vocal cord.
Primary laryngeal lymphoma is a rare diagnosis, accounting for less than 1% of all laryngeal tumors. Approximately 100 cases have been reported in the English-language literature. A variety of lymphoma classifications have been described, including diffuse large B-cell lymphoma, NK/T-cell lymphoma, ...
Why it matters: Recent peer-reviewed research on Follicular lymphoma that may be relevant for patients and caregivers.
- International journal of molecular medicine Jan 23, 2026
Epigenetic dysregulation of B‑cells in autoimmune diseases and lymphomas (Review).
B‑lymphocytes (B‑cells) develop from hematopoietic stem cells in the bone marrow or fetal liver and differentiate into antibody‑secreting cells and memory B‑cells upon encountering antigens in peripheral lymphoid organs. Throughout this process, the expression of lineage&...
Why it matters: Recent peer-reviewed research on Follicular lymphoma that may be relevant for patients and caregivers.
- Blood advances Jan 14, 2026
Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with MYC/BCL2 rearrangements, DLBCL morphology.
High-grade B-cell lymphoma with "double-hit" MYC and BCL2 rearrangements (HGBCL-DH-BCL2) is associated with poor outcomes following standard chemoimmunotherapy, prompting dose-intensive regimen use. However, the benefit of intensification is unclear due to rarity precluding randomized trials, and se...
Why it matters: Recent peer-reviewed research on Follicular lymphoma that may be relevant for patients and caregivers.
- The American journal of surgical pathology Jan 13, 2026
Pediatric-Type Follicular Lymphoma of the Conjunctiva: Shared Histologic and Molecular Features With the Nodal Counterpart.
Pediatric-type follicular lymphoma (PTFL) is a rare and indolent B-cell lymphoma that largely affects children and young adults. Although typically nodal, rare similar lesions have been reported in the conjunctiva, but differential diagnosis with follicular hyperplasia and other low-grade B-cell lym...
Why it matters: Recent peer-reviewed research on Follicular lymphoma that may be relevant for patients and caregivers.
More on Follicular lymphoma
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.